Literature DB >> 21642504

Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation.

Cuneyt K Buharalioglu1, Chi Young Song, Fariborz A Yaghini, Hafiz U B Ghafoor, Mustafa Motiwala, Tusita Adris, Anne M Estes, Kafait U Malik.   

Abstract

Spleen tyrosine kinase (Syk), expressed in endothelial cells, has been implicated in migration and proliferation and in vasculogenesis. This study was conducted to determine the contribution of Syk and the underlying mechanism to the angiogenic effect of ANG II and VEGF. Angiogenesis was determined by tube formation from the endothelial cell line EA.hy926 (EA) and human umbilical vein endothelial cells (HUVECs) and microvessel sprouting in rat aortic rings. ANG II (10 nM), EGF (30 ng/ml), and VEGF (50 ng/ml) stimulated EA cells and HUVECs to form tubular networks and increased aortic sprouting; these effects were blocked by VEGF receptor-1 and Flt-1 antibody (Flt-1/Fc) but not by the VEGF receptor-2 (Flk-1) antagonist SU-1498. ANG II increased the phosphorylation of Flt-1 but not Flk-1, whereas VEGF increased the phosphorylation of both receptors in EA cells and HUVECs. VEGF expression elicited by ANG II was not altered by Flt-1/Fc or SU-1498. EGF stimulated tube formation from EA cells and HUVECs and Flt-1 phosphorylation and aortic sprouting, which were blocked by the EGF receptor antagonist AG-1478 and Flt-1/Fc but not by SU-1498. ANG II-, EGF-, and VEGF-induced tube formation and aortic sprouting were attenuated by the Syk inhibitor piceatannol and by Syk short hairpin interfering (sh)RNA and small interfering RNA, respectively. ANG II, EGF, and VEGF increased Syk phosphorylation, which was inhibited by piceatannol and Syk shRNA in EA cells and HUVECs. Neither piceatannol nor Syk shRNA altered ANG II-, EGF-, or VEGF-induced phosphorylation of Flt-1. These data suggest that ANG II stimulates angiogenesis via transactivation of the EGF receptor, which promotes the phosphorylation of Flt-1 and activation of Syk independent of VEGF expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21642504      PMCID: PMC3191073          DOI: 10.1152/ajpheart.01018.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  39 in total

1.  A critical role for Syk in endothelial cell proliferation and migration.

Authors:  R Inatome; S Yanagi; T Takano; H Yamamura
Journal:  Biochem Biophys Res Commun       Date:  2001-08-10       Impact factor: 3.575

Review 2.  Structure and function of Syk protein-tyrosine kinase.

Authors:  K Sada; T Takano; S Yanagi; H Yamamura
Journal:  J Biochem       Date:  2001-08       Impact factor: 3.387

Review 3.  Inflammation and angiotensin II.

Authors:  Yusuke Suzuki; Marta Ruiz-Ortega; Oscar Lorenzo; Monica Ruperez; Vanesa Esteban; Jesus Egido
Journal:  Int J Biochem Cell Biol       Date:  2003-06       Impact factor: 5.085

4.  Cardiac myofibroblasts: a novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR.

Authors:  Vishnu Chintalgattu; Devi M Nair; Laxmansa C Katwa
Journal:  J Mol Cell Cardiol       Date:  2003-03       Impact factor: 5.000

5.  Piceatannol, a Syk-selective tyrosine kinase inhibitor, attenuated antigen challenge of guinea pig airways in vitro.

Authors:  Cherng-Jye Seow; Sung-Chian Chue; W S Fred Wong
Journal:  Eur J Pharmacol       Date:  2002-05-17       Impact factor: 4.432

Review 6.  The role of angiotensin II in regulating vascular structural and functional changes in hypertension.

Authors:  Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

7.  Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells.

Authors:  Ralf Benndorf; Rainer H Böger; Süleyman Ergün; Anna Steenpass; Thomas Wieland
Journal:  Circ Res       Date:  2003-07-24       Impact factor: 17.367

8.  [Influence of angiotensin I on angiogenesis in vitro in the rat].

Authors:  J L Pasquié; N Biousse; A Mimran; B Jover
Journal:  Arch Mal Coeur Vaiss       Date:  2003 Jul-Aug

Review 9.  Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders.

Authors:  Aernout Luttun; Marc Tjwa; Peter Carmeliet
Journal:  Ann N Y Acad Sci       Date:  2002-12       Impact factor: 5.691

10.  A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library.

Authors:  Mayada El-Mousawi; Lioudmila Tchistiakova; Ludmila Yurchenko; Grzegorz Pietrzynski; Maria Moreno; Danica Stanimirovic; Darakhshan Ahmad; Valery Alakhov
Journal:  J Biol Chem       Date:  2003-09-02       Impact factor: 5.157

View more
  16 in total

Review 1.  Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications.

Authors:  Biagio Ricciuti; Jennifer Foglietta; Rita Chiari; Amirhossein Sahebkar; Maciej Banach; Vanessa Bianconi; Matteo Pirro
Journal:  Med Oncol       Date:  2017-12-04       Impact factor: 3.064

2.  Atorvastatin reverses the dysfunction of human umbilical vein endothelial cells induced by angiotensin II.

Authors:  Haiming Dang; Bangrong Song; Ran Dong; Hongjia Zhang
Journal:  Exp Ther Med       Date:  2018-10-11       Impact factor: 2.447

3.  Regulation of the Renin-Angiotensin System Pathways in the Human Decidua.

Authors:  Yu Wang; Eugenie R Lumbers; Shane D Sykes; Kirsty G Pringle
Journal:  Reprod Sci       Date:  2014-12-28       Impact factor: 3.060

4.  The Estrogen Receptor α Cistrome in Human Endometrium and Epithelial Organoids.

Authors:  Sylvia C Hewitt; San-Pin Wu; Tianyuan Wang; Madhumita Ray; Marja Brolinson; Steven L Young; Thomas E Spencer; Alan DeCherney; Francesco J DeMayo
Journal:  Endocrinology       Date:  2022-09-01       Impact factor: 5.051

Review 5.  Protein kinases and associated pathways in pluripotent state and lineage differentiation.

Authors:  Melina Shoni; Kathy O Lui; Demetrios G Vavvas; Michael G Muto; Ross S Berkowitz; Nikolaos Vlahos; Shu-Wing Ng
Journal:  Curr Stem Cell Res Ther       Date:  2014       Impact factor: 3.828

6.  Prostaglandin E2 and vascular endothelial growth factor A mediate angiogenesis of human ovarian follicular endothelial cells.

Authors:  Heidi A Trau; Mats Brännström; Thomas E Curry; Diane M Duffy
Journal:  Hum Reprod       Date:  2016-01-05       Impact factor: 6.918

7.  AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.

Authors:  Ahmed Alhusban; Anna Kozak; Adviye Ergul; Susan C Fagan
Journal:  J Pharmacol Exp Ther       Date:  2012-12-04       Impact factor: 4.030

8.  Angiotensin II increases angiogenesis by NF-κB-mediated transcriptional activation of angiogenic factor AGGF1.

Authors:  Wenxia Si; Wen Xie; Wenbing Deng; Yi Xiao; Sadashiva S Karnik; Chengqi Xu; Qiuyun Chen; Qing Kenneth Wang
Journal:  FASEB J       Date:  2018-04-11       Impact factor: 5.191

9.  Interactions between vascular endothelial growth factor and neuroglobin.

Authors:  Kunlin Jin; Xiao Mao; Lin Xie; David A Greenberg
Journal:  Neurosci Lett       Date:  2012-05-11       Impact factor: 3.046

Review 10.  Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: Evidence from a meta-analysis including 55 studies.

Authors:  Hong Sun; Tao Li; Rongyuan Zhuang; Weimin Cai; Yuanting Zheng
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.